Investment firm Catalio has hired Renata Skerlj as CEO for a new startup Rhapsogen focused on autoimmune diseases.[1] Skerlj previously served as an executive at Expansion Therapeutics and X4 Pharmaceuticals.[1] Rhapsogen also received funding, although the exact amount is not disclosed.[1] Alumis announced that its oral TYK2 inhibitor envudeucitinib met its skin-clearing efficacy goals in two phase 3 clinical trials in patients with plaque psoriasis.[1] The company plans to file for FDA approval in the second half of the year.[1] Arrowhead Pharmaceuticals reported that their RNAi gene-suppression drugs helped obese patients lose fat in early studies.[1] These results may increase competition in the field of long-term weight loss drugs, but more data are needed.[1]